
Opinion|Videos|January 8, 2024
TROPION-Breast01: DatoDXd in Previously Treated Inoperable/Metastatic HR+/HER2- Breast Cancer
Medical oncologists discuss results from the TROPION-Breast01 study investigating Dato-DXd (datopotamab deurxtecan) in patients with previously treated inoperable or metastatic HR+/HER2- breast cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
2
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
3
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
4
Lung Cancer News Roundup: June 2026
5












































